How to start and continuing empagliflozin therapy in the cardiologist’s office? Review article
Article Sidebar
Published:
Jun 30, 2020
Keywords:
sodium-glucose co-transporter 2 (SGLT2) inhibitors, blood pressure, metabolic effects, empagliflozin, cardiovascular safety
Main Article Content
Abstract
Research results place SGLT2 inhibitors amongst primary drugs in the treatment of type 2 diabetes. Empagliflozin is one of the most effective medicines in this group. It is favored by inducing beneficial effects, such as weight loss, and rapid glucose lowering. The recent EMPA-REG OUTCOME study also proved cardiovascular safety of empagliflozin.
Article Details
How to Cite
Gaciong , Z., & Dzida , G. (2020). How to start and continuing empagliflozin therapy in the cardiologist’s office?. Medycyna Faktow (J EBM), 13(2(47), 152-155. https://doi.org/10.24292/01.MF.0220.3
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Deedwania P, Acharya T. Cardiovascular Protection with Anti-hyperglycemic Agents. Am J Cardiovasc Drugs. 2019. http://doi.org/10.1007/s40256-019-00325-9.
2. Ferraro RA, Nass CM, Dudum R et al. What Clinicians Need to Know About the Cardiovascular Effects of the Most Recent Classes of Drugs Used for Type 2 Diabetes. Am J Med. 2019. http://doi.org/10.1016/j.amjmed.2019.02.050.
3. Zelniker TA, Braunwald E. Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes. JACC State-of-the-Art Review. J Am Coll Cardiol. 2018; 72: 1845-55.
4. Zinman B, Wanner C, Lachin JM et al. EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373: 2117-28.
5. Filippatos TD, Liontos A, Papakitsou I et al. SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses. Postgrad Med. 2019; 131: 82-8.
6. Roden M, Weng J, Eilbracht J et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2013; 1: 208-19.
7. Ferrannini E, Muscelli E, Frascerra S et al. Metabolic response to sodium-glucosecotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014; 124: 499-508.
2. Ferraro RA, Nass CM, Dudum R et al. What Clinicians Need to Know About the Cardiovascular Effects of the Most Recent Classes of Drugs Used for Type 2 Diabetes. Am J Med. 2019. http://doi.org/10.1016/j.amjmed.2019.02.050.
3. Zelniker TA, Braunwald E. Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes. JACC State-of-the-Art Review. J Am Coll Cardiol. 2018; 72: 1845-55.
4. Zinman B, Wanner C, Lachin JM et al. EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373: 2117-28.
5. Filippatos TD, Liontos A, Papakitsou I et al. SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses. Postgrad Med. 2019; 131: 82-8.
6. Roden M, Weng J, Eilbracht J et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2013; 1: 208-19.
7. Ferrannini E, Muscelli E, Frascerra S et al. Metabolic response to sodium-glucosecotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014; 124: 499-508.